Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

PROK ProKidney Corp. Class A Ordinary Shares
$1.99 -6.57% -0.14
Notify me if price changes either direction
Interactive Brokers Logotype

Buy PROK stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 595.7M
Enterprise value 1.4B
Trailing PE -3.1935484178605
Forward PE -3.3476884
PEG Ratio 0.22354838925023
Enterprise to EBITDA -8.266
Enterprise to revenue 1828.442
Price to book MRQ 0.83962875514322
Price to sales TTM 861.2597

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 744.0K
EBITDA -164576992
Diluted EPS TTM -0.55
Total Cash (MRQ) 271.7M
Current ratio (MRQ) 10.322
Operating Cash Flow (TTM) -111775000

PROK trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months
Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.